GWANC
EPRX

Guardian Wealth Advisors (North Carolina)’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Guardian Wealth Advisors (North Carolina)’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76K Buy
10,500
+500
+5% +$4.03K ﹤0.01% 415
2025
Q4 		$75.5K Buy
+10,000
New +$61.6K ﹤0.01% 366

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Guardian Wealth Advisors (North Carolina)'s EPRX Position: Q1 2026 in Review

Guardian Wealth Advisors (North Carolina) increased its Eupraxia Pharmaceuticals (EPRX) stake by 5% in Q1 2026, buying an estimated $4.03K and bringing the position to 10,500 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #415.

Guardian Wealth Advisors (North Carolina) first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Guardian Wealth Advisors (North Carolina) held 10,500 shares of Eupraxia Pharmaceuticals worth $76K as of Q1 2026.
  • Guardian Wealth Advisors (North Carolina) bought 500 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $4.03K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Guardian Wealth Advisors (North Carolina)'s portfolio in Q1 2026, its #415 holding.
  • Guardian Wealth Advisors (North Carolina) first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Guardian Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 15 May 2026.